Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee

Expansion Leverages Daxor's ezBVA Lab to Deliver 98% Accurate Diagnostics with Zero Capital Investment  Oak Ridge, TN, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion into the outpatient cardiology market with the opening of a new BVA program at a leading healthcare facility in Southern Middle Tennessee. This integration brings Daxor's state-of-the-art testing to a high-volume preventative care setting, driving clinical excellence in chronic disease management.

GlobeNewsWire • 11 hours ago

Daxor Corporation Announces $9 Million Registered Direct Offering

OAK RIDGE, TN, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NasdaqCM: DXR) (“Daxor” or the “Company”) announced today that it has entered into a definitive agreement with fundamental investors for the purchase and sale of an aggregate of 765,958 shares of its common stock (the “Shares”) at a purchase price per Share of $11.75. The offering is expected to close on or about January 26, 2026, subject to the satisfaction of customary closing conditions.

GlobeNewsWire • Jan 23, 2026

Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer

Continued Integration of ezBVA Lab Service and On-Site Analyzer Deployment Signals Accelerating Market Traction Oak Ridge, TN, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces the expansion of its Blood Volume Analysis (BVA) platform into three new, prestigious facilities. This milestone demonstrates the accelerating market adoption of BVA's pivotal role in precision fluid management, leading to improved patient outcomes and reduced healthcare costs.

GlobeNewsWire • Nov 25, 2025

Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit

Summit Features a Select Group of 40 Promising Healthcare Companies at Premier Small-Cap Investor Event OAK RIDGE, TN, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that President and Chief Executive Officer Michael Feldschuh will engage institutional investors at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 – 23, 2025, at the Hard Rock Hotel in New York City.

GlobeNewsWire • Oct 21, 2025

Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA

Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces significant commercial momentum and clinical validation following the Heart Failure Society of America (HFSA) Annual Scientific Meeting.

GlobeNewsWire • Sep 30, 2025

Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting

Additional New Clinical Data To Be Presented Driving a New Standard of Care in Volume Measurement OAK RIDGE, Tenn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces it will exhibit at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Minneapolis, Minnesota, from September 26-29, 2025.

GlobeNewsWire • Sep 23, 2025

Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care

Study Demonstrates That Clinical Assessments of Fluid Status Are Often Inaccurate, Highlighting the Urgent Need for BVA and Other More Reliable Tools in Landmark Pilot Study Oak Ridge, TN, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today highlighted the significant findings of a new pilot study published in the Journal of Critical Care.

GlobeNewsWire • Sep 4, 2025

Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Oak Ridge, TN, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C.

GlobeNewsWire • Sep 3, 2025

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

Oak Ridge, TN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh.

GlobeNewsWire • Sep 2, 2025

Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System

Management Expects High Demand Driven by Speed, Simplicity, and Clinical Precision Oak Ridge, TN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces FDA 510(k) clearance (K251087) for its patent-pending next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (BVA). The new Daxor BVA™ device quantifies a patient's blood volume against patient-specific norms, enabling precise fluid management across a broad spectrum of clinical conditions affecting millions of patients each year.

GlobeNewsWire • Aug 7, 2025